Literature DB >> 24952601

Utility of contrast-enhanced ultrasound with perflubutane for diagnosing the macroscopic type of small nodular hepatocellular carcinomas.

Toshifumi Tada1, Takashi Kumada, Hidenori Toyoda, Takanori Ito, Yasuhiro Sone, Yuji Kaneoka, Atsuyuki Maeda, Seiji Okuda, Katsuhiko Otobe, Kenichi Takahashi.   

Abstract

OBJECTIVE: To clarify the diagnostic value of contrast-enhanced ultrasound (CEUS) with perflubutane in the macroscopic classification of small nodular hepatocellular carcinomas (HCCs).
METHODS: A total of 99 surgically resected nodular HCCs with a maximum diameter of 3 cm or less were analysed. HCCs were macroscopically categorized as simple nodular (SN) and non-SN. CEUS findings were evaluated during the arterial phase (vascularity, level and shape of enhancement), portal phase (presence or absence of washout) and post-vascular phase (echo intensity and shape).
RESULTS: Sixty-eight HCCs were categorized as SN and the remaining 31 were categorized as non-SN. For diagnosis of non-SN HCC, the areas under the receiver operating characteristic curve (A z) value for the shape of enhancement in the late arterial phase and the shape of the post-vascular image were 0.824 (95 % confidence interval [CI] 0.721-0.895) and 0.878 (95 % CI 0.788-0.933), respectively. The A z value for the combination of the shape of enhancement in the late arterial phase and the shape of the post-vascular image for the diagnosis of non-SN HCC was 0.907 (95 % CI 0.815-0.956), corresponding to a high diagnostic value.
CONCLUSION: CEUS can provide high-quality imaging assessment for determining the macroscopic classification of small nodular HCCs. KEY POINTS: • Non-SN is one of the poor prognostic factors in patients with HCC • Assessment of macroscopic type provides valuable information for the management of HCC • CEUS can provide high-quality imaging assessment for macroscopic classification of HCC • For non-SN HCC diagnosed using CEUS, hepatectomy is preferred as curative treatment.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24952601     DOI: 10.1007/s00330-014-3254-2

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  34 in total

1.  Phagocytosis of ultrasound contrast agent microbubbles by Kupffer cells.

Authors:  Kyosuke Yanagisawa; Fuminori Moriyasu; Takeo Miyahara; Miyata Yuki; Hiroko Iijima
Journal:  Ultrasound Med Biol       Date:  2007-02       Impact factor: 2.998

2.  Usefulness of Sonazoid contrast-enhanced ultrasonography for hepatocellular carcinoma: comparison with pathological diagnosis and superparamagnetic iron oxide magnetic resonance images.

Authors:  Keiko Korenaga; Masaaki Korenaga; Matakazu Furukawa; Takahiro Yamasaki; Isao Sakaida
Journal:  J Gastroenterol       Date:  2009-04-23       Impact factor: 7.527

3.  Ultrasound-guided treatments under low acoustic power contrast harmonic imaging for hepatocellular carcinomas undetected by B-mode ultrasonography.

Authors:  Hitoshi Maruyama; Masanori Takahashi; Hiroyuki Ishibashi; Hidehiro Okugawa; Shinichiro Okabe; Masaharu Yoshikawa; Osamu Yokosuka
Journal:  Liver Int       Date:  2008-09-18       Impact factor: 5.828

4.  Predictor for histological microvascular invasion of hepatocellular carcinoma: a lesson from 229 consecutive cases of curative liver resection.

Authors:  Susumu Eguchi; Mitsuhisa Takatsuki; Masaaki Hidaka; Akihiko Soyama; Tetsuo Tomonaga; Izumi Muraoka; Takashi Kanematsu
Journal:  World J Surg       Date:  2010-05       Impact factor: 3.352

Review 5.  Ultrasound diagnostic criteria for hepatic tumors.

Authors: 
Journal:  J Med Ultrason (2001)       Date:  2014-01       Impact factor: 1.314

Review 6.  Measuring the accuracy of diagnostic systems.

Authors:  J A Swets
Journal:  Science       Date:  1988-06-03       Impact factor: 47.728

Review 7.  Radiofrequency ablation for hepatocellular carcinoma: updated review in 2010.

Authors:  Masatoshi Kudo
Journal:  Oncology       Date:  2010-07-08       Impact factor: 2.935

8.  Gross appearance of hepatocellular carcinoma reflects E-cadherin expression and risk of early recurrence after surgical treatment.

Authors:  Jun Inayoshi; Takafumi Ichida; Soichi Sugitani; Yasunori Tsuboi; Takuya Genda; Nobuyuki Honma; Hitoshi Asakura
Journal:  J Gastroenterol Hepatol       Date:  2003-06       Impact factor: 4.029

9.  Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey.

Authors:  Iwao Ikai; Shigeki Arii; Masamichi Kojiro; Takafumi Ichida; Masatoshi Makuuchi; Yutaka Matsuyama; Yasuni Nakanuma; Kiwamu Okita; Masao Omata; Kenichi Takayasu; Yoshio Yamaoka
Journal:  Cancer       Date:  2004-08-15       Impact factor: 6.860

10.  The gross classification of hepatocellular carcinoma: usefulness of contrast-enhanced US.

Authors:  Kinuyo Hatanaka; Yasunori Minami; Masatoshi Kudo; Tatsuo Inoue; Hobyung Chung; Seiji Haji
Journal:  J Clin Ultrasound       Date:  2014-01       Impact factor: 0.910

View more
  3 in total

1.  Usefulness of combining gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging and contrast-enhanced ultrasound for diagnosing the macroscopic classification of small hepatocellular carcinoma.

Authors:  Tomoki Kobayashi; Hiroshi Aikata; Masahiro Hatooka; Kei Morio; Reona Morio; Hiromi Kan; Hatsue Fujino; Takayuki Fukuhara; Keiichi Masaki; Atsushi Ohno; Noriaki Naeshiro; Takashi Nakahara; Yohji Honda; Eisuke Murakami; Tomokazu Kawaoka; Masataka Tsuge; Akira Hiramatsu; Michio Imamura; Yoshiiku Kawakami; Hideyuki Hyogo; Shoichi Takahashi; Kazuaki Chayama
Journal:  Eur Radiol       Date:  2015-06-03       Impact factor: 5.315

Review 2.  Tumor Markers for Hepatocellular Carcinoma: Simple and Significant Predictors of Outcome in Patients with HCC.

Authors:  Hidenori Toyoda; Takashi Kumada; Toshifumi Tada; Yasuhiro Sone; Yuji Kaneoka; Atsuyuki Maeda
Journal:  Liver Cancer       Date:  2015-03       Impact factor: 11.740

Review 3.  Role of contrast-enhanced ultrasonography with Sonazoid for hepatocellular carcinoma: evidence from a 10-year experience.

Authors:  Hitoshi Maruyama; Tadashi Sekimoto; Osamu Yokosuka
Journal:  J Gastroenterol       Date:  2015-12-22       Impact factor: 6.772

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.